Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 1/20 | 0.50 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 16/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667689 | 0.89 | MAPK1 (0.45) | MAPK1PRKDCATMATR | |
| SCHEMBL667742 | 0.84 | MAPK1 (0.70) | MAPK1PRKDCATMATRDYRK1A | |
| SCHEMBL10141749 | 0.84 | MAPK1 (0.61) | MAPK1PRKDCATMATR | |
| SCHEMBL10141784 | 0.84 | PIP4K2A (0.42) | MAPK1PRKDCATMATR | |
| SCHEMBL667161 | 0.82 | MAPK1 (0.44) | MAPK1PRKDCATMATR | |
| SCHEMBL667688 | 0.82 | MAPK1 (0.48) | MAPK1PRKDCATMATR | |
| SCHEMBL9985630 | 0.81 | MAPK1 (0.47) | MAPK1PRKDCATMATR | |
| SCHEMBL9986182 | 0.81 | MAPK1 (0.54) | MAPK1PRKDCATMATR | |
| SCHEMBL10141812 | 0.80 | MAPK1 (0.49) | MAPK1PRKDCATMATR | |
| SCHEMBL9985558 | 0.80 | MAPK1 (0.46) | MAPK1PRKDCATMATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009723-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009723-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009723-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-01-14 | — | — | US | disclosed |
| US-20140288347-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288347-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288347-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-25 | — | — | US | disclosed |
| US-8623869-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623869-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623869-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120046295-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046295-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046295-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288347-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | IKBKE 209/4885TBK1 15/4885MAPK1 122/4885 |
| US-20120046295-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | IKBKE 209/4885TBK1 15/4885MAPK1 122/4885 |
| US-20160009723-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | IKBKE 209/4885TBK1 15/4885MAPK1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.